Parkinson's Disease — Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
Citation(s)
A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease